← Back to Clinical Trials
Recruiting NCT04003038

NCT04003038 Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04003038
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Body Mass Index Greater Than or Equal to 30
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2019-05-02
Primary Completion 2028-04-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Negative Pressure Wound TherapyWound Care Management

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2019-05-02 with a primary completion date of 2028-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This trial studies the safety and how well negative pressure wound therapy works in healing the abdominal incision in obese patients undergoing free flap breast reconstruction surgery. Using negative pressure wound therapy (NPWT) instead of standard dressing (bandages) may improve wound healing at the surgical site in the abdomen where tissue was collected for breast reconstruction surgery.

Eligibility Criteria

Inclusion Criteria: * Patients undergoing a free abdominal flap, including a superficial inferior epigastric artery (SIEA), deep inferior epigastric artery perforator (DIEP), or muscle-sparing transverse rectus abdominus myocutaneous (MS-TRAM) flap for breast reconstruction. * Patients are willing and able to give consent. * Body mass index (BMI) greater than or equal to 30.0. Exclusion Criteria: * Patients who are unable to provide consent. * Patients who are suspected or known to be pregnant. * Known allergy to topical adhesives.

Contact & Investigator

Central Contact

Edward H Chang

✉ eichang@mdanderson.org

📞 713-794-1247

Principal Investigator

Edward H Chang

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT04003038 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Body Mass Index Greater Than or Equal to 30. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04003038 currently recruiting?

Yes, NCT04003038 is actively recruiting participants. Contact the research team at eichang@mdanderson.org for enrollment information.

Where is the NCT04003038 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT04003038 clinical trial?

NCT04003038 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Edward H Chang at M.D. Anderson Cancer Center. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology